cvi42 Auto Imaging vs ElucidVivo A.3
AI Verdict
Choose cvi42 Auto Imaging if…
Choose cvi42 Auto Imaging if your clinical practice requires a comprehensive, multi-modality solution for analyzing a wide range of cardiovascular MR and CT images. This tool is ideal for labs needing AI-enabled automated contouring, detailed cardiac function assessment (including strain and flow), and general plaque assessment across both MR and CT modalities.
View cvi42 Auto Imaging →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your primary focus is on in-depth, quantitative analysis of arterial plaque composition and stability specifically from CT angiography. This tool is best suited for clinicians who need to precisely quantify plaque components like Lipid-Rich Necrotic Core (LRNC) and calcifications, stratify atherosclerosis patients, and optimize treatment decisions based on histology-validated plaque characteristics and derived FFRct.
View ElucidVivo A.3 →For a physician evaluating AI tools for cardiovascular imaging, cvi42 Auto Imaging and ElucidVivo A.3 offer distinct strengths. cvi42 Auto Imaging provides a comprehensive suite for analyzing both cardiac MR and CT images, encompassing function, flow, tissue characterization, and plaque assessment across multiple modalities. It excels in streamlining overall clinical workflows with automated contouring, 3D visualization, and smart reporting. This makes it ideal for practices requiring a broad, vendor-neutral solution for diverse cardiovascular imaging needs.
In contrast, ElucidVivo A.3 specializes in the quantitative analysis of arterial plaque composition and stability from CT angiography. Its key practical difference lies in its ability to objectively quantify specific plaque components like Lipid-Rich Necrotic Core (LRNC) and validate these measurements against histology, offering a deeper insight into atherosclerosis patient stratification and treatment optimization. Therefore, a physician primarily focused on detailed plaque characterization and risk assessment for atherosclerosis, particularly where histological validation is paramount, would find ElucidVivo A.3 more tailored to their needs. For broader cardiovascular imaging analysis and workflow efficiency across MR and CT, cvi42 Auto Imaging would be the more suitable choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cvi42 Auto Imaging | ElucidVivo A.3 |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | On-premise, Stand-alone, Networked environment. Cloud compatibility is mentioned as a feature, but recent FDA clearances for modules like cvi42 | Plaque emphasize on-premise deployment for data control. | Software application, likely on-premise or cloud-based (standard for medical imaging software, not explicitly detailed, but integrates with PACS/EMR). |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cvi42 Auto Imagingcvi42 Auto Imaging emphasizes streamlined clinical workflows, simplified and smart reporting with infographics, and intuitive post-processing analysis, which directly enhances user experience. While ElucidVivo A.3's interface follows typical clinical workflow patterns, some sources suggest its intricate analysis may require a steeper learning curve.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 offers a highly specialized and validated approach to arterial plaque analysis, objectively quantifying components like Lipid-Rich Necrotic Core and deriving FFRct, all validated against ground-truth histology. This provides profound and predictive clinical insights for atherosclerosis patient stratification and treatment optimization. While cvi42 Auto Imaging offers comprehensive cardiovascular analysis across modalities, ElucidVivo A.3's depth and unique validation in its niche provide superior clinical impact.
Pricing & Value
TieBoth tools require direct contact for pricing, indicating a lack of public transparency regarding costs. Neither provides sufficient public information on specific pricing models, licensing structures, or value propositions to distinguish between them in this dimension.
Enterprise Readiness
cvi42 Auto Imagingcvi42 Auto Imaging explicitly details flexible deployment options including on-premise, stand-alone, networked, and cloud compatibility with an emphasis on local data control. It boasts full DICOM connectivity, HL7 compatibility, and vendor-neutrality, along with ISO 13485:2016 and MDSAP certifications, demonstrating robust integration capabilities and quality management. ElucidVivo A.3 also integrates with PACS/EMR and mentions cloud/on-premise deployment with SOC 2 / HIPAA-aligned data protection, but Tool A's comprehensive detail and certifications give it a slight edge.
Innovation
ElucidVivo A.3ElucidVivo A.3 demonstrates greater innovation through its unique, histologically validated quantitative analysis of arterial plaque composition and stability, including the objective quantification of specific plaque components like LRNC and the derivation of FFRct. This provides novel predictive insights for personalized atherosclerosis management, moving beyond traditional diagnostic assistance. While cvi42 Auto Imaging leverages AI for automation, ElucidVivo A.3's specialized, validated approach to plaque characterization is more cutting-edge in its focus.
Support & Docs
cvi42 Auto Imagingcvi42 Auto Imaging explicitly highlights its 'great customer service' and 'Real People, Real Time Support' from a 'highly-qualified global team' offering multi-language support across time zones. It also provides accessible cvi42 Documentation, including system requirements. ElucidVivo A.3 does not provide any explicit information regarding its customer support or documentation in the available data.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cvi42 Auto Imaging | ElucidVivo A.3 |
|---|---|---|
| Tool Name | cvi42 Auto Imaging | ElucidVivo A.3 |
| Company | Circle Cardiovascular Imaging | Elucid Bioimaging |
| Core Purpose | AI-powered software for comprehensive analysis of cardiovascular MR and CT images, aiding in precise diagnosis, plaque quantification, and streamlined clinical workflows. | FDA-cleared AI-powered medical image analysis system for quantitative analysis of arterial plaque composition and stability from CT angiography, assisting physicians in atherosclerosis patient stratification and optimizing treatment decisions. |
| Supported Imaging Modalities | Multi-modality support (MR, CT) | CT angiography |
| Primary Plaque Analysis Capabilities | Cardiac CT analysis (Plaque Assessment), Quantitative analysis (plaque) | AI-powered quantitative analysis of arterial plaque, objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, visualizes lesion-level plaque composition. |
| Other Key Cardiovascular Analysis Capabilities | AI-enabled automated contouring and segmentation, Cardiac MR analysis (Function, Flow, Tissue Characterization, Strain), Cardiac CT analysis (Calcium Scoring, Coronary Arteries), Vascular CT analysis (diagnosis, planning, surveillance), Quantitative analysis (volume, mass, function, signal intensity). | Aids in stratifying patients with atherosclerosis, derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. |
| Unique Differentiators/Validation | Simplified and smart reporting with infographics and CAD-RADS classification, vendor-neutral compatibility. | Validated on ground-truth histology. |
Videos
Demos, reviews, and walkthroughs featuring cvi42 Auto Imaging and ElucidVivo A.3.